| Literature DB >> 27914657 |
Ryan Ungaro1, Saurabh Mehandru2, Patrick B Allen3, Laurent Peyrin-Biroulet4, Jean-Frédéric Colombel5.
Abstract
Ulcerative colitis is a chronic inflammatory disease affecting the colon, and its incidence is rising worldwide. The pathogenesis is multifactorial, involving genetic predisposition, epithelial barrier defects, dysregulated immune responses, and environmental factors. Patients with ulcerative colitis have mucosal inflammation starting in the rectum that can extend continuously to proximal segments of the colon. Ulcerative colitis usually presents with bloody diarrhoea and is diagnosed by colonoscopy and histological findings. The aim of management is to induce and then maintain remission, defined as resolution of symptoms and endoscopic healing. Treatments for ulcerative colitis include 5-aminosalicylic acid drugs, steroids, and immunosuppressants. Some patients can require colectomy for medically refractory disease or to treat colonic neoplasia. The therapeutic armamentarium for ulcerative colitis is expanding, and the number of drugs with new targets will rapidly increase in coming years.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27914657 PMCID: PMC6487890 DOI: 10.1016/S0140-6736(16)32126-2
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321